NEWSRELEASE

BIOSENSORSCOMPLETESOFFERINGOFS$300MILLION4.875%FIXEDRATENOTES DUE2017
Singapore, 23 January 2013 Biosensors International Group, Ltd. (Biosensors or the Company, Bloomberg:BIGSP;Reuters:BIOS.SI;SGX:B20),adeveloper,manufacturerandmarketerofinnovative medical devices, today announced that Biosensors Investment (Singapore) Pte. Ltd, a whollyowned subsidiary of the Company (the Issuer), has issued S$300 million in principal amount of4.875% fixed ratenotesdue2017(theNotes). The transaction was successfully priced following an intraday book building exercise on 14 January 2013, with an oversubscribed order book of total value exceeding S$2.5 billion. The Notes will mature on 23 January 2017and will bear a fixed interest rate of 4.875% per annum, payable semiannually in arrear. The coupon rate was well within the initial indicative rate, which was in the region of 5.25%, reflecting the quality of the order book. The Notes were issued under the S$800 million Multicurrency MediumTermNoteProgramme(MTNProgramme)establishedbytheIssueron4January2013. The net proceeds from the issue of the Notes (after deducting issue expenses) will be used for general corporate purposes of the Company and its subsidiaries, and as further specified in the information memorandum dated 4 January 2013 issued in connection with the MTN Programme, and also the pricingsupplementdated16January2013inconnectionwiththeNotes. We are pleased that strong investor demand has enabled us to complete this bond offering, said Biosensors CEO, Dr. Jack Wang. This offering not only allows us to take advantage of the lower interest rates available in the credit markets, but also significantly strengthens our liquidity and balance sheet, and at the same time improves our financial flexibility to capitalize on potential opportunities.Theresultisasuccessforbothourbondholdersandshareholders. ###
Media/InvestorRelationsContact BiosensorsInternationalGroup Mr.WongTeckYenn Director,InvestorRelations Tel:(65)62135708 Email:ty.wong@biosensors.com
Page1of2

 AboutBiosensorsInternationalGroup,Ltd Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients lives through pioneering medical technologythatpushesforwardtheboundariesofinnovation. With the increasing use of the BioMatrix family of drugeluting stents and the recent launch of our Axxess selfexpanding bifurcation drugeluting stent, we are rapidly emerging as a leader in the global coronary stent market.ThedevelopmentoftheBioFreedomdrugcoatedstentwillfurtherreinforceourmarketposition. All three stents incorporate Biolimus A9 (BA9), an antirestenotic drug developed and patented by Biosensors specifically for use with drugeluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a selfexpanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymerfree stent abluminally coated with BA9, is currentlyundergoingclinicalevaluation. Formoreinformation,pleasevisitwww.biosensors.com. ForwardLookingStatements Certain statements herein include forwardlooking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forwardlooking statements generally can be identified by the use of forward looking terminology, such as may, will, expect, intend, estimate, anticipate, believe, project or continue or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retainqualityemployeesasBiosensors grows;andeconomicandpoliticalconditionsglobally.Actualresultsmay differ materially from those discussed in, or implied by, the forwardlooking statements. The forwardlooking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new,changingorunanticipatedeventsorcircumstances.

Page2of2